Our study revealed that PD-L1 might be a potential prognostic biomarker for recurrent NPC patients, and advanced re-stage, anemia might represent as candidate biomarkers for evaluating patients’ response to anti PD-1 / PD-L1-treatment. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.